Definition
Lung cancer is the most frequently diagnosed cancer and a leading cause of cancer mortality worldwide. For therapeutic purposes, lung cancer is divided into two classes, non-small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC). The three main subtypes of NSCLC are adenocarcinoma, squamous-cell carcinoma, and large-cell carcinoma with adenocarcinoma being the most common histological subtype. Lung cancer pharmacogenomics is the study of the role of lung cancer genetics in drug response. Pharmacogenomics encompasses a genome-wide association approach, incorporates genomics and epigenetics, and deals with the effects of multiple genes on drug response. The aim of lung cancer pharmacogenomics is to develop means to optimize lung cancer therapy with respect to the genotype of the patient, ensuring maximum efficacy and minimal adverse effects. Deeper understanding of the...
This is a preview of subscription content, log in via an institution to check access.
References
Karachaliou N, Rosell R (2014) Systemic treatment in EGFR-ALK NSCLC patients: second line therapy and beyond. Cancer Biol Med 11:173–181
Karachaliou N, Rosell R, Morales-Espinosa D, Viteri S (2014) Systemic treatment in EGFR-ALK NSCLC patients: second line therapy and beyond. Expert Rev Anticancer Ther 14:807–815
Karachaliou N, Rosell R, Carcereny E (2015) How to personalize chemotherapy in stage IV NSCLC? In: New therapeutic strategies in lung cancers, pp 119–129. Springer International Publishing: Switzerland
Moran T, Wei J, Cobo M, Qian X, Domine M, Zou Z, Bover I, Wang L, Provencio M, Yu L, Chaib I, You C et al (2014) Two biomarker-directed randomized trials in European and Chinese patients with non-small-cell lung cancer: the BRCA1-RAP80 Expression Customization (BREC) studies. Ann Oncol Off J Eur Soc Med Oncol ESMO 25(11):2147–55
Rosell R Dynamic evolution of ALK positive non-small cell lung cancers and management of associated brain metastases [podcast]. J Clin Oncol. January 26, 2015. doi:10.1200/JCO.2011.55.5555
Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez JM, Porta R, Cobo M et al (2012) Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13:239–246
Rosell R, Bivona TG, Karachaliou N (2013) Genetics and biomarkers in personalisation of lung cancer treatment. Lancet 382:720–731
Rosell R, Karachaliou N, Wolf J, Ou SH (2014) ALK and ROS1 non-small-cell lung cancer: two molecular subgroups sensitive to targeted therapy. Lancet Respir Med 2:966–968
See Also
(2012) Targeted therapy. In: Schwab M (ed) Encyclopedia of cancer. Springer, Berlin/Heidelberg, p 3610. doi:10.1007/978-3-642-16483-5_5677
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer-Verlag Berlin Heidelberg
About this entry
Cite this entry
Karachaliou, N., Rosell, R. (2015). Lung Cancer Pharmacogenomics. In: Schwab, M. (eds) Encyclopedia of Cancer. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-27841-9_7207-1
Download citation
DOI: https://doi.org/10.1007/978-3-642-27841-9_7207-1
Received:
Accepted:
Published:
Publisher Name: Springer, Berlin, Heidelberg
Online ISBN: 978-3-642-27841-9
eBook Packages: Springer Reference Biomedicine and Life SciencesReference Module Biomedical and Life Sciences